FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for

FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melan

http://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma fda.gov

RSS Hunter • Aug 6